CeriBell (NASDAQ:CBLL) Shares Down 2.6% – Should You Sell?

CeriBell (NASDAQ:CBLL)’s share price fell 2.6% during mid-day trading on Thursday . The company traded as low as $26.28 and last traded at $26.29. 85,309 shares were traded during trading, a decline of 65% from the average session volume of 246,355 shares. The stock had previously closed at $26.98.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Canaccord Genuity Group started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. began coverage on CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 target price on the stock. William Blair initiated coverage on CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. TD Cowen upped their target price on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Bank of America started coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $32.60.

CeriBell Trading Down 2.6 %

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. On average, equities research analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.